
    
      The primary objective of the first stage of the TINSAL-T2D trial is to select a dose of
      salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic
      control. The trial is a multicenter, single mask lead-in, double masked placebo controlled
      dose ranging study, comparing salsalte to placebo over 3 months.
    
  